Mammalian animal models for Duchenne muscular dystrophy

被引:136
作者
Willmann, Raffaella [1 ]
Possekel, Stefanie [2 ]
Dubach-Powell, Judith [2 ]
Meier, Thomas [2 ]
Ruegg, Markus A. [1 ]
机构
[1] Univ Basel, Biozentrum, CH-4056 Basel, Switzerland
[2] Santhera Pharmaceut, CH-4410 Liestal, Switzerland
关键词
Duchenne muscular dystrophy; Animal models; Mouse; Dog; Cat; GRMD; mdx; NECROSIS-FACTOR-ALPHA; 3 MOUSE MODELS; MDX MICE; SKELETAL-MUSCLE; DEFICIENT MICE; DYSTROPHIN/UTROPHIN-DEFICIENT; NATURAL-HISTORY; DOUBLE MUTANT; CANINE MODEL; LONG-TERM;
D O I
10.1016/j.nmd.2008.11.015
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Duchenne muscular dystrophy (DMD) is a fatal neuromuscular disease that affects boys and leads to early death. In the quest for new treatments that improve the quality Of life and in the search for a possible definitive cure, the rise of animal models Plays undoubtedly in important role. Therefore, a number of different mammalian models for DMD have been described. Much knowledge oil the molecular mechanisms Underlying the disease has arisen from studies in these animals, However, the rise of different models does nor often allow a direct comparison of results obtained in preclinical trials and therefore hinders a straightforward translational research. In the frame of "TREAT-NMD", a European Network of Excellence addressing the fragmentation in the assessment and treatment of neuromuscular diseases. we compare here the currently used mammalian animal models for DMD with the aim of selecting and recommending the most appropriate ones for preclinical efficacy testing of new therapeutic strategies. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:241 / 249
页数:9
相关论文
共 90 条
[1]  
AMBROSIO CE, 2008, NEUROMUSCUL DISORD
[2]   FUNCTIONAL REGENERATION IN THE HINDLIMB SKELETAL-MUSCLE OF THE MDX MOUSE [J].
ANDERSON, JE ;
BRESSLER, BH ;
OVALLE, WK .
JOURNAL OF MUSCLE RESEARCH AND CELL MOTILITY, 1988, 9 (06) :499-515
[3]   Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle Degeneration similar to that observed in Duchenne muscular dystrophy [J].
Araki, E ;
Nakamura, K ;
Nakao, K ;
Kameya, S ;
Kobayashi, O ;
Nonaka, I ;
Kobayashi, T ;
Katsuki, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 238 (02) :492-497
[4]   Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy [J].
Bia, BL ;
Cassidy, PJ ;
Young, ME ;
Rafael, JA ;
Leighton, B ;
Davies, KE ;
Radda, GK ;
Clarke, K .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1999, 31 (10) :1857-1862
[5]   The neurobiology of Duchenne muscular dystrophy:: learning lessons from muscle? [J].
Blake, DJ ;
Kröger, S .
TRENDS IN NEUROSCIENCES, 2000, 23 (03) :92-99
[6]   Functional improvement of dystrophic muscle by myostatin blockade [J].
Bogdanovich, S ;
Krag, TOB ;
Barton, ER ;
Morris, LD ;
Whittemore, LA ;
Ahima, RS ;
Khurana, TS .
NATURE, 2002, 420 (6914) :418-421
[7]   Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse [J].
Briguet, A ;
Courdier-Fruh, I ;
Foster, M ;
Meier, T ;
Magyar, JP .
NEUROMUSCULAR DISORDERS, 2004, 14 (10) :675-682
[8]   X-CHROMOSOME-LINKED MUSCULAR-DYSTROPHY (MDX) IN THE MOUSE [J].
BULFIELD, G ;
SILLER, WG ;
WIGHT, PAL ;
MOORE, KJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1984, 81 (04) :1189-1192
[9]   First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant [J].
Burdi, R ;
Didonna, MP ;
Pignol, B ;
Nico, B ;
Mangieri, D ;
Rolland, JF ;
Camerino, C ;
Zallone, A ;
Ferro, P ;
Andreetta, F ;
Confalonieri, P ;
De Luca, A .
NEUROMUSCULAR DISORDERS, 2006, 16 (04) :237-248
[10]   Enhanced expression of the α7β1 integrin reduces muscular dystrophy and restores viability in dystrophic mice [J].
Burkin, DJ ;
Wallace, GQ ;
Nicol, KJ ;
Kaufman, DJ ;
Kaufman, SJ .
JOURNAL OF CELL BIOLOGY, 2001, 152 (06) :1207-1218